IL1B and cholangiocarcinoma: Further, corroborating our findings, LECs when treated with CCA-CM also showed increased gene expression of CXCL5 (p ≤ 0.0001) in addition to increased expression of critical inflammatory agents implicated in tumor-associated lymphangiogenesis such as IL1B, IL6, IL8 (Figure 2C).